/PRNewswire/ – Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that Martha H. Marsh has been appointed to its board of directors.
Marsh served as the president and CEO of Stanford Hospital & Clinics for eight years, until her retirement in 2010. Prior to joining Stanford, Marsh served in hospital leadership positions at University of California Davis Medical Center, University of Pennsylvania Health System and Dartmouth-Hitchcock Medical Center.
“Martha is a welcome addition to our board of directors, which will benefit from her 30 years of experience and insight into serving patients in an increasingly complex and ever-evolving healthcare system,” said Michael A. Mussallem, Edwards’ chairman and CEO. “Martha’s deep knowledge and unique leadership will add a valuable perspective as our board considers the execution of our patient-focused innovation strategy.”
Currently, Marsh serves on the boards of directors of AMN Healthcare Services, Inc., and Owens & Minor Inc., a leading healthcare logistics company. She also served on the board of Thoratec Corp. until its Oct. 8 acquisition by St. Jude Medical, Inc.
Marsh has master’s degrees in public health administration and accounting from Columbia University and a bachelor’s degree in history from the University of Rochester.
Source: Edwards Lifesciences Corporation
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
